MA08.03 Immunotherapy Alone or with Chemotherapy in Advanced NSCLC? Utility of Clinical Factors and Blood-Based Host Immune Profiling.

W. Akerley; N. Nagajothi; P. Walker; R. Mitchell; R. Page; J. Tan; J. Dubay; E. Santos; W. Brenner; P. Rich; J. Orsini; E. Pauli; E. Schaefer

doi:10.1016/J.JTHO.2021.01.190

MA08.03 Immunotherapy Alone or with Chemotherapy in Advanced NSCLC? Utility of Clinical Factors and Blood-Based Host Immune Profiling.

W. Akerley
, N. Nagajothi
, P. Walker
, R. Mitchell
, R. Page
, J. Tan
, J. Dubay
, E. Santos
, W. Brenner
, P. Rich
, J. Orsini
, E. Pauli
, E. Schaefer

Huntsman Cancer Institute
Mercy Medical Cancer Center, Canton/OH/US
East Carolina University
Virginia Cancer Institute, Midlothian/VA/US
The Center for Cancer and Blood Disorders, Fort Worth/TX/US
Wayne State University
"lewis & Faye Manderson Cancer Center at Dch Regional Medical Center, Tuscaloosa/AL/US
Thoracic, Florida Precision Oncology, Boca Raton/AL/US
Boca Raton Regional Hospital
Cancer Treatment Centers of America
Newark Beth Israel Medcl Ctr, Newark/US
Clearview Cancer Institute, Huntsville/AL/US
Highlands Oncology Group, Fayetteville/AR/US

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Thoracic Oncology
Volume	16
Issue number	3
DOIs	https://doi.org/10.1016/J.JTHO.2021.01.190
State	Published - Mar 1 2021
Externally published	Yes

Disciplines

Medicine and Health Sciences
Oncology

Access to Document

10.1016/J.JTHO.2021.01.190License: Unspecified

Cite this

Akerley, W., Nagajothi, N., Walker, P., Mitchell, R., Page, R., Tan, J., Dubay, J., Santos, E., Brenner, W., Rich, P., Orsini, J., Pauli, E., & Schaefer, E. (2021). MA08.03 Immunotherapy Alone or with Chemotherapy in Advanced NSCLC? Utility of Clinical Factors and Blood-Based Host Immune Profiling. Journal of Thoracic Oncology, 16(3). https://doi.org/10.1016/J.JTHO.2021.01.190

Akerley, W, Nagajothi, N, Walker, P, Mitchell, R, Page, R, Tan, J, Dubay, J, Santos, E, Brenner, W, Rich, P, Orsini, J, Pauli, E & Schaefer, E 2021, 'MA08.03 Immunotherapy Alone or with Chemotherapy in Advanced NSCLC? Utility of Clinical Factors and Blood-Based Host Immune Profiling.', Journal of Thoracic Oncology, vol. 16, no. 3. https://doi.org/10.1016/J.JTHO.2021.01.190

@article{4ae208008ffe4d7689975afae0fb9bb5,

title = "MA08.03 Immunotherapy Alone or with Chemotherapy in Advanced NSCLC? Utility of Clinical Factors and Blood-Based Host Immune Profiling.",

author = "W. Akerley and N. Nagajothi and P. Walker and R. Mitchell and R. Page and J. Tan and J. Dubay and E. Santos and W. Brenner and P. Rich and J. Orsini and E. Pauli and E. Schaefer",

note = "Immune checkpoint inhibitors (ICI) have revolutionized cancer care with greater overall survival (OS) in patients with advanced stage non-small cell lung cancer (aNSCLC). However, even for patients with good ECOG performance status (PS) 0-1 and high PD-L1 expression, the overall response rate to single-agent ICI in the treatment na{\"i}ve population is only 45\%.",

year = "2021",

month = mar,

day = "1",

doi = "10.1016/J.JTHO.2021.01.190",

language = "American English",

volume = "16",

journal = "Journal of Thoracic Oncology",

number = "3",

}

TY - JOUR

T1 - MA08.03 Immunotherapy Alone or with Chemotherapy in Advanced NSCLC? Utility of Clinical Factors and Blood-Based Host Immune Profiling.

AU - Akerley, W.

AU - Nagajothi, N.

AU - Walker, P.

AU - Mitchell, R.

AU - Page, R.

AU - Tan, J.

AU - Dubay, J.

AU - Santos, E.

AU - Brenner, W.

AU - Rich, P.

AU - Orsini, J.

AU - Pauli, E.

AU - Schaefer, E.

N1 - Immune checkpoint inhibitors (ICI) have revolutionized cancer care with greater overall survival (OS) in patients with advanced stage non-small cell lung cancer (aNSCLC). However, even for patients with good ECOG performance status (PS) 0-1 and high PD-L1 expression, the overall response rate to single-agent ICI in the treatment naïve population is only 45%.

PY - 2021/3/1

Y1 - 2021/3/1

UR - https://www.jto.org/article/S1556-0864(21)00232-X/fulltext

U2 - 10.1016/J.JTHO.2021.01.190

DO - 10.1016/J.JTHO.2021.01.190

M3 - Article

VL - 16

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 3

ER -

MA08.03 Immunotherapy Alone or with Chemotherapy in Advanced NSCLC? Utility of Clinical Factors and Blood-Based Host Immune Profiling.

Disciplines

Access to Document

Other files and links

Cite this